Just like the billionaire, Flávio Figueiredo Assis sold a company in the financial sector to invest in his own automobile manufacturer, LECAR SÃO PAULO, Jan. 22, 2024 /PRNewswire/ — Entrepreneur Flávio Figueiredo Assis promises to make history by launching the first originally Brazilian electric car. More than contributing to changing the energy matrix and positively… Continue reading Known as the Brazilian Elon Musk, entrepreneur creates electric car manufacturer in Brazil
Category: Newswire
Quark Expeditions Introduces M/V Ocean Explorer to its Polar Fleet
“Going beyond in the polar regions requires the best expedition team operating the best ships,” says Andrew White, President of Quark Expeditions. “And we’ve got both. Ocean Explorer is the perfect addition to our fleet—for adventure, for luxury, and for leading-edge technology, this purpose-built polar expedition ship truly delivers for our discerning polar explorers.” Ocean… Continue reading Quark Expeditions Introduces M/V Ocean Explorer to its Polar Fleet
Hospital Infection Therapeutics Market is to grow by USD 3.10 billion, Special drug designations to boost growth – Technavio
NEW YORK, Jan. 23, 2024 /PRNewswire/ –The hospital infection therapeutics market is estimated to grow by USD 3.10 billion from 2022 to 2027, growing at a CAGR of 4.98%, according to Technavio. Special drug designations are a key factor in boosting growth. Pharmaceuticals used to treat hospital-acquired infections and therapeutic candidates in development for these conditions have received special… Continue reading Hospital Infection Therapeutics Market is to grow by USD 3.10 billion, Special drug designations to boost growth – Technavio
Solvias führt Freigabetests für die weltweit erste CRISPR-basierte Gen-Editierungstherapie durch
Globaler Anbieter unterzeichnet langfristiges Abkommen mit Vertex Pharmaceuticals für CASGEVY™ KAISERAUGST, Schweiz, 23. Januar 2024 /PRNewswire/ — Solvias, ein globaler Anbieter von Chemie-, Herstellungs- und Kontrollanalysen (CMC), gab heute bekannt, dass es analytische Freigabetests für die weltweit erste genom-editierte CRISPR/Cas9-Zelltherapie durchführen wird. Das Unternehmen hat eine langfristige Vereinbarung mit Vertex Pharmaceuticals für CASGEVY™ (exagamglogene autotemcel oder… Continue reading Solvias führt Freigabetests für die weltweit erste CRISPR-basierte Gen-Editierungstherapie durch
Solvias va effectuer des tests de libération sur la première thérapie d’édition génique CRISPR au monde
Un fournisseur mondial signe un accord à long terme avec Vertex Pharmaceuticals pour CASGEVYMC KAISERAUGST, Suisse, 23 janvier 2024 /PRNewswire/ — Solvias, fournisseur mondial d’analyses de chimie, de fabrication et de contrôle (CMC), a annoncé aujourd’hui qu’elle effectuera des services de tests analytiques de libération sur la première thérapie cellulaire d’édition génomique CRISPR/Cas9 au monde. La… Continue reading Solvias va effectuer des tests de libération sur la première thérapie d’édition génique CRISPR au monde
Solvias voert releasetests uit voor ‘s werelds eerste CRISPR-behandeling met genbewerkingstechnologie
Wereldwijde leverancier tekent langetermijncontract met Vertex Pharmaceuticals voor CASGEVY™ KAISERAUGST, Zwitserland, 23 januari 2024 /PRNewswire/ — Solvias, een wereldwijde leverancier van analysediensten op het gebied van chemie, productie en controle (CMC), kondigde vandaag aan dat het testanalyses zal uitvoeren voor de release van ‘s werelds eerste celbehandeling met behulp van CRISPR/Cas9-genbewerkingstechnologie. Het bedrijf heeft een… Continue reading Solvias voert releasetests uit voor ‘s werelds eerste CRISPR-behandeling met genbewerkingstechnologie
Solvias to Perform Release Testing on World’s First CRISPR-based Gene-Editing Therapy
Global Provider Signs Long-Term Agreement with Vertex Pharmaceuticals for CASGEVY™ KAISERAUGST, Switzerland, Jan. 23, 2024 /PRNewswire/ — Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today that it will perform analytical release testing services on the world’s first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex… Continue reading Solvias to Perform Release Testing on World’s First CRISPR-based Gene-Editing Therapy
Solvias to Perform Release Testing on World’s First CRISPR-based Gene-Editing Therapy
Global Provider Signs Long-Term Agreement with Vertex Pharmaceuticals for CASGEVY™ KAISERAUGST, Switzerland, Jan. 23, 2024 /PRNewswire/ — Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today that it will perform analytical release testing services on the world’s first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex… Continue reading Solvias to Perform Release Testing on World’s First CRISPR-based Gene-Editing Therapy
Ares, Eurazeo, Barings Among Top 2023 European Direct Lenders – Lower Mid Market Deals Account for 80% of Transactions Despite Record Unitranche Size Raised
NEW YORK, Jan. 23, 2024 /PRNewswire/ — Reorg, a global provider of credit data, analysis and intelligence, has released its 2023 European Direct Lender league tables data. The league tables rank European direct lender activity in 2023 across factors including region and sub-region, loan size and sector. Additionally, the report explores overall deal flow in 2023… Continue reading Ares, Eurazeo, Barings Among Top 2023 European Direct Lenders – Lower Mid Market Deals Account for 80% of Transactions Despite Record Unitranche Size Raised
Colin Crooks, vétéran de Shell, est nommé PDG du fournisseur de solutions environnementales ACT
Colin Crooks rejoint ACT alors que le marché de la décarbonisation devrait tripler pour atteindre 4 000 milliards de dollars d’ici 2028 AMSTERDAM, 23 janvier 2024 /PRNewswire/ — Colin Crooks, ancien PDG et président du conseil d’administration de Shell Energy Retail et plus récemment vice-président principal de Shell pour les énergies renouvelables et les solutions énergétiques en Europe, rejoindra le groupe ACT… Continue reading Colin Crooks, vétéran de Shell, est nommé PDG du fournisseur de solutions environnementales ACT